NL-OMON41538已完成2 期
Mechanism of action study of anti-IL17 therapy in spondyloarthritis: impact on cellular and molecular pathways of synovial inflammation and tissue remodelling. - MoA IL-17 in Spondyloarthritis
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-Male or non-pregnant/non-lactating females age 18-70
- •- Diagnosis of SpA according to ESSG criteria and/or ASAS criteria
- •- Active disease defined by *1 swollend and * 1 tender joint, and at least 1 swollen knee or ankle joint at baseline
排除标准
- •- Evidence for infectious or malignant process (on chest X ray/MRI etc)
- •- Pts taking opioid angalgetics
- •- Previous IL-17 therapy exposure
- •- Previous use of celldepleting therapies, biological immunomodulants (except for a.TNF)
- •- no more then 50% of included patients are allowed to be previously exposed to (1) TNF blocking agent
- •- Significant medical problems or diseases
研究者
相似试验
进行中（未招募）
不适用
Mechanism of action study of anti-IL17 treatment in spondyloarthritis.MedDRA version: 16.1Level: LLTClassification code 10032155Term: Other inflammatory spondylopathiesSystem Organ Class: 100000004859MedDRA version: 16.1Level: LLTClassification code 10070759Term: SpondylopathySystem Organ Class: 100000004859SpondyloarthritisEUCTR2013-002709-79-NLAcademic Medical Center, Department of Rheumatology
已完成
3 期
Mechanism of Action of Anti-IL17 Therapy in Peripheral SpondyloarthritisSpondylarthropathiesNCT03358134Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)20
招募中
2 期
se of Anti-IL-17 in patients with Covid-19 associated pneumoniaCoronavirus infection, unspecifiedCoronavirus infectionsSevere acute respiratory syndrome (SARS)Severe Acute Respiratory SyndromeB34.2C01.925.782.600.550.200C01.748.730RBR-5vpyh4Pesquisador
进行中（未招募）
1 期
Treatment of non-type 2 CRSwNP with anti-IL-17 antibody (secukinumab)Chronic rhinosinusitis with nasal polypsCTIS2023-505711-20-00Tartu University Hospital4
已完成
1 期
Single-arm Study to Assess a Potential Effect of Anti-IL-17 (Secukinumab) in the Treatment of Pyoderma GangrenosumPyoderma GangrenosumNCT02733094Technical University of Munich8